Skip to main content

Cepheid Inks Group Purchasing Deal with Novation

NEW YORK (GenomeWeb News) – Cepheid said today that it has signed a group purchasing deal with Novation for its GeneXpert System and Xpert MRSA (methicillin-resistant Staphylococcus aureus) tests.
 
Under the agreement, customers of Novation, a large group purchasing organization that serves hospital systems including VHA, University HealthSystem Consortium, and Provista, will be able to purchase the molecular diagnostics instrument and tests at undisclosed pre-negotiated prices. According to a Cepheid statement, Novation purchasing power represents 49 percent of admissions and 44 percent of staffed beds in the US.
 
The pact follows last week’s announcement of a similar arrangement between Cepheid and Premier, a group purchasing organization that has more than 1,500 hospitals in its network.
 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.